Nordic Nanovector

Nordic Nanovector is a biopharmaceutical company dedicated to extending and improving the lives of patients with hematological cancers through the development and commercialization of innovative targeted therapies. The company's lead clinical-stage product is β-clusterin, the first in a new class of antibody radionuclide conjugates (ARCs), designed to enhance and complement current treatment options for non-Hodgkin lymphoma (NHL). NHL represents an unmet medical need and an orphan drug opportunity.